Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities

The Innovative Medicines Initiative (IMI) funds for 5 years a consortium consisting of 13 European pharmaceutical companies and 12 academic groups and SMEs to develop information technologies-based solutions for improved  toxicity prediction of new drug candidates.